Restrictive Transfusion Strategy after Cardiac Surgery.
Norddine Zeroual, Cinderella Blin, Marine Saour...
https://pubmed.ncbi.nlm.nih.gov/33475735/Actively Recruiting
Led by University Hospital, Lille · Updated on 2026-09-17
236
Participants Needed
4
Research Sites
39 weeks
Total Duration
This research aims to compare two strategies for red blood cell transfusion in patients receiving veno-arterial extracorporeal membrane oxygenation VA-ECMO support for refractory cardiogenic shock. The study evaluates whether an individualized approach based on central venous oxygen saturation ScVO2 is more effective in reducing blood transfusion compared to a conventional method using a predefined hemoglobin threshold. This multicenter randomized controlled trial focuses on red blood cell consumption, mortality, morbidity, and cost-effectiveness in this critical patient group. Participants will be assigned to one of two groups an individualized transfusion strategy where transfusions occur if ScVO2 drops below 65% after optimizing oxygen saturation, volume, ECMO output, fever, anxiety, and pain or a conventional strategy where transfusions are given if hemoglobin levels fall below 9 gdL. Transfusions may also be performed in both groups under specific conditions such as massive bleeding, STEMI, hyperlactatemia, low hemoglobin below 7 gdL, or worsening neurological condition related to oxygen delivery. During the study, participants will be monitored closely with assessments of red blood cell transfusion amounts per day, hemoglobin and ScVO2 levels, mortality rates up to 90 days, and other clinical outcomes including organ function and complications. The study includes laboratory tests, clinical evaluations, and cost-effectiveness analyses. Monitoring continues from randomization until ECMO weaning, with follow-up assessments extending to 90 days and beyond, ensuring comprehensive evaluation of patient outcomes and safety.
CONDITIONS
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
M
Mouhamed MOUSSA, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Lille
Lead Sponsor
Amiens University Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 28 days or until VA-ECMO weaning
Participants receive one of two transfusion strategies while supported by VA-ECMO: an individualized approach based on ScVO2 levels or a conventional method based on hemoglobin thresholds.
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Norddine Zeroual, Cinderella Blin, Marine Saour...
https://pubmed.ncbi.nlm.nih.gov/33475735/Lars B Holst, Marie W Petersen, Nicolai Haase...
https://pubmed.ncbi.nlm.nih.gov/25805204/Mary S Leffell, Deborah Kim, Renato M Vega...
https://pubmed.ncbi.nlm.nih.gov/24300013/Hyoung Soo Kim, Sunghoon Park
https://pubmed.ncbi.nlm.nih.gov/31723612/Cecile Aubron, Allen C Cheng, David Pilcher...
https://pubmed.ncbi.nlm.nih.gov/23594433/Guillaume Guimbretière, Amedeo Anselmi, Antoine Roisne...
https://pubmed.ncbi.nlm.nih.gov/30444173/Benoit Vallet, Emmanuel Robin, Gilles Lebuffe
https://pubmed.ncbi.nlm.nih.gov/20236457/Michael A Mazzeffi, Kenichi Tanaka, Alia Roberts...
https://pubmed.ncbi.nlm.nih.gov/30181084/Marc-Olivier Fischer, Pierre-Grégoire Guinot, Stéphane Debroczi...
https://pubmed.ncbi.nlm.nih.gov/34862002/Michael Mazzeffi, John Greenwood, Kenichi Tanaka...
https://pubmed.ncbi.nlm.nih.gov/26443879/University Hospital, Lille
Lead Sponsor
Amiens University Hospital
Collaborating Sponsor